RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway.
Sun F, Wang X, Hu J, Liu J, Wang X, Jia W, Yu Z, Gao L, Dou B, Zhao R, Feng T, Wang X, Zhang W, Liu H, Liu K, Shao Y, Dong X, Han B.
Sun F, et al. Among authors: wang x.
Oncogene. 2022 Jun;41(23):3239-3250. doi: 10.1038/s41388-022-02332-8. Epub 2022 May 4.
Oncogene. 2022.
PMID: 35508542